Product Demonstrations

A majority of Ebola survivors suffer some form of long-term brain health problems, according to a new study.

Patients who were successfully treated for the disease were found to have neurological issues six months later.

The most common problems included muscle pain, headaches, memory loss and depressed moods, but in rare cases patients were suicidal, the US researchers said.

Researchers have developed a low-cost and portable diagnostic device that can be used to detect Ebola infection and many other diseases. The device could be particularly useful to monitor endemic, epidemic and pandemic disease outbreaks in resource-limited developing countries that need portable diagnostic equipment that functions outside the hospital.

Read more at: http://www.oneindia.com/international/low-cost-portable-device-that-can-detect-ebola-2020618.html

Antibodies targeting the Ebola virus surface glycoprotein (EBOV GP) are implicated in protection against lethal disease, but the characteristics of the human antibody response to EBOV GP remain poorly understood. We isolated and characterized 349 GP-specific monoclonal antibodies (mAbs) from the peripheral B cells of a convalescent donor who survived the 2014 EBOV Zaire outbreak. Remarkably, 77% of the mAbs neutralize live EBOV, and several mAbs exhibit unprecedented potency. Structures of selected mAbs in complex with GP reveal a site of vulnerability located in the GP stalk region proximal to the viral membrane. Neutralizing antibodies (NAbs) targeting this site show potent therapeutic efficacy against lethal EBOV challenge in mice. The results provide a framework for the design of new EBOV vaccine candidates and immunotherapies.

(complet article)